Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomized, double-blind, placebo-controlled phase 2 trial of pentosan polysulfate sodium in patients with MPS-VI

Next Previous
Trial Profile

A multi-centre, randomized, double-blind, placebo-controlled phase 2 trial of pentosan polysulfate sodium in patients with MPS-VI

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pentosan polysulfate (Primary)
  • Indications Mucopolysaccharidosis VI
  • Focus Adverse reactions
  • Sponsors Paradigm Biopharma

    • Most Recent Events

    • 19 Aug 2022 New trial record
    • 12 Aug 2022 According to a Paradigm Biopharma media release, An additional safety review will be completed once 3 patients in this age group have been enrolled and reach the specified timepoint. A positive additional safety review will support the inclusion of subjects in the 5- to 9-year- old age group. These additional age groups are highly relevant to future potential therapeutic registration as the disease is detected and can manifest early in children and adolescents.
    • 12 Aug 2022 According to a Paradigm Biopharma media release, To date, three adult subjects have been enrolled in the study and fifty-two weeks of cumulative data across the subjects have been assessed. Under the clinical protocol, a mandated safety review has been completed with no serious adverse events reported. This is a key milestone for the phase 2 study, which now allows the inclusion of subjects aged 9 to 16 years to assess the safety and tolerability of PPS among paediatric populations.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top